The endocannabinoid system:A new pharmacological target for obesity treatment?  

内源性大麻素系统——治疗肥胖的药物新靶点(英文)

作　　者：胡佳[1] 朱超[1] 黄矛[1] 

机构地区：[1]第二军医大学基础部新药评价中心,上海200433

出　　处：《Neuroscience Bulletin》2009年第3期153-160,共8页神经科学通报（英文版）

基　　金：supported by the Study Grant (2007) for Medical Students of Second Military Medical University,China

摘　　要：Being a great threaten for human health, obesity has become a pandemic chronic disease. There have been several therapeutic treatments for this social health issue, including diet and exercise therapy, medication and surgery, among which the diet is still the most common way. However, none of these therapeutic measures available is ideal, making it necessary to find an effective medical treatment. The endocannabinoid system, which is well known for its contributions in certain mental processes such as relaxation, amelioration of pain and anxiety, and sedation initiation, has been recently reported to play an essential role in regulating appetite and metabolism to maintain energy balance, leading to the belief that endocannabinoid system is closely related to obesity. This new discovery deepens our understanding of obesity, and provides us with a new direction for clinical obesity treatment. Rimonabant is an antagonist for CB1, and has entered the market in some countries. However, although effective as an anti-obesity drug, rimonabant also causes obviously adverse side-effects, thus is being doubted and denied for medical usage.肥胖已成为一种世界范围内流行的慢性病,严重危害人类健康。目前,肥胖的治疗包括饮食、运动、用药和手术,其中饮食和运动疗法仍然是基础。然而,这些方法都不理想。寻找治疗肥胖的有效药物成为一种新的趋势。有研究表明,内源性大麻素系统在调节食欲、代谢和保持机体能量平衡方面发挥着重要作用,与肥胖的发生发展有着密切的联系。它使人们对肥胖有了更深一步的认识,也为肥胖的临床治疗提供了新的思路。大麻素CB1受体拮抗剂利莫那班在显示有效临床减肥作用的同时,还有明显的副作用,难以成为减肥新药。

关 键 词：OBESITY weight loss ENDOCANNABINOIDS cannabinoid receptor cannabinoid CB1 receptor antagonist anti-obesity agents RIMONABANT 

分 类 号：R589.2[医药卫生—内分泌]